Navigation Links
Postmenopausal women with higher testosterone levels
Date:11/4/2009

Chevy Chase, MD Postmenopausal women who have higher testosterone levels may be at greater risk of heart disease, insulin resistance and the metabolic syndrome compared to women with lower testosterone levels, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). This new information is an important step, say researchers, in understanding the role that hormones play in women's health.

"For many years, androgens like testosterone were thought to play a significant role in men only and to be largely irrelevant in women," said Anne Cappola, MD, of the University of Pennsylvania School of Medicine in Philadelphia. "It is now largely accepted that premenopausal women with polycystic ovary syndrome, a condition in which androgens are elevated, have increased health risks. However, the clinical relevance of testosterone in women over the age of 65 had remained uncertain until this recent study."

In this study, researchers measured levels of testosterone in 344 women, aged 65-98 years. They found that women with the highest testosterone levels in the top 25 percent of this study group were three times as likely to have coronary heart disease compared to women with lower testosterone levels. These women were also three times as likely to have a group of metabolic risk factors called the metabolic syndrome compared to women with lower testosterone levels.

The connection between higher levels of testosterone and these health risks may be explained by the researcher's finding of a greater degree of insulin resistance in women with the highest testosterone levels. Insulin resistance is a metabolic disturbance in which the body does not use insulin efficiently and is itself a risk factor for the metabolic syndrome and cardiovascular disease.

"Because of the observational aspect of this study, we cannot discern if testosterone is a marker or mediator of cardiovascular disease in this population," said Cappola. "Further studies are needed to determine if a causal relationship exists between testosterone and insulin resistance and to provide more insight into the role testosterone plays in the pathogenesis of cardiovascular disease in women."


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
2. QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
3. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
4. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
5. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
6. Exercise Boosts Quality of Life in Postmenopausal Women
7. Multivitamin use may offer no benefit in postmenopausal women
8. UNC study: Postmenopausal womens loss of sexual desire affects health, quality of life
9. High insulin levels raise risk of breast cancer in postmenopausal women
10. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
11. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... ... 21, 2017 , ... The VIA Agency , a ... Theravent, Inc. , the makers of a revolutionary new device clinically proven ... now working to expand distribution in anticipation of a national launch. VIA will ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... to overcome their mental health struggles. The Alive team uses advanced behavioral sciences ... approach in dealing with a mental health struggle is based on 10 modalities ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... anticipated Regional Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. ... offering physicians and healthcare providers an opportunity to learn about cutting edge treatments, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology: